Chapter 16 of 25
- Applicator ± interstitial needles placed with pain control
- MRI / CT checks anatomy
- Individual dose plan protects nearby organs
- Temporary source delivers treatment, then is removed
What you will learn
Distinguish intracavitary and interstitial techniques; understand a treatment visit; know why an external-beam boost is usually not equivalent.
Choosing the applicator
Intracavitary brachytherapy uses an applicator within the uterine canal together with vaginal components, such as a ring or ovoids. Interstitial treatment adds or uses needles placed into tissue to cover disease that cannot be adequately treated with an intracavitary arrangement alone. Combined techniques can help with larger, asymmetric or residual tumours. The choice depends on anatomy and response, not on which device sounds more advanced.
Image-guided adaptive brachytherapy uses MRI or CT to define the remaining tumour and nearby organs for that application. The plan adapts to changes during treatment. The team evaluates cumulative dose from external-beam radiation and brachytherapy, including exposure to bladder, rectum and bowel. These are specialist planning tasks, not doses patients should calculate themselves.
What a session involves
Before insertion, the team explains consent, fasting if needed, anaesthesia or sedation, bladder catheterization and pain management. Applicators are positioned and checked with imaging. During high-dose-rate treatment, a small radioactive source temporarily travels through the applicator channels under remote control. Staff monitor you, and you can communicate with them. The source is withdrawn after delivery.
Applications and treatment sessions vary between centres and plans. Some involve repeated insertions; others deliver more than one fraction during an admission. Ask how long you will remain in bed, whether you can eat, how discomfort will be treated and whether you need someone to take you home. After temporary high-dose-rate treatment the source is removed, so you do not remain radioactive. Other techniques may have different instructions.
Why access matters
For definitive radiotherapy of an intact cervical cancer, brachytherapy is a core part of curative care. It achieves a dose distribution that an ordinary external-beam boost generally cannot reproduce safely. Modern external-beam techniques should not be presented as an equivalent convenient replacement. If the local centre lacks brachytherapy, ask about timely referral to a centre that provides it.
Rare exceptional circumstances may require an alternative strategy, but the team should explain the expected compromise and why brachytherapy cannot be delivered. Do not omit it merely because the tumour has shrunk or symptoms have improved. Response is one input to planning, not proof that the remaining component is unnecessary.
Safety, recovery and longer-term effects
Temporary cramping, spotting and urinary discomfort can occur. Insertion carries risks such as bleeding, infection, anaesthetic complications and, rarely, perforation; imaging and experienced teams reduce risk. Report severe or worsening pain, heavy bleeding, fever, inability to urinate or concerning discharge promptly. Follow the department's instructions on activity and vaginal care after removal.
Later effects overlap with pelvic radiotherapy: vaginal shortening or narrowing, dryness, bowel and urinary changes, and rarely fistula or tissue injury. Discuss sexual health respectfully and early. Dilator use, lubricants, pelvic therapy and hormone options may help when individually appropriate; they should not be painful exercises imposed without explanation.
Misconception and common question
“If the external radiation worked, brachytherapy is optional” is usually incorrect in definitive cervical treatment. Are interstitial needles a sign of failure? No: they can be a planned way to obtain better tumour coverage while protecting organs.
Take-home messages
Confirm brachytherapy access at the start of treatment. Ask about anaesthesia, imaging and logistics. Know the urgent symptoms and the plan for pelvic rehabilitation afterward.
References and review status
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
- EMBRACE — Image-guided adaptive brachytherapy research and protocols
- NCI — Radiation therapy for cancer
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy